Malignant melanoma requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, immunotherapy, and small molecule-targeted therapies. Treatment decisions are influenced by disease stage, resectability, and in the unresectable or metastatic setting, BRAF-mutation status. The malignant melanoma landscape has transformed since 2011: CTLA-4 inhibitors, PD-1 inhibitors, and BRAF/MEK inhibitors are now key treatment options for unresectable disease while adjuvant cytokine therapy remains the mainstay for early-stage disease. This analysis provides insight on current use of approved therapies for malignant melanoma in the EU5 and on factors driving physicians’ prescribing decisions.
Related Reports
Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast
The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol-Myers Squibb), as well as
Malignant Melanoma - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into...
Malignant Melanoma - Current Treatment - Detailed, Expanded Analysis (US)
Stage of disease, resectability of the primary tumor, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma. BRAF/MEK inhibitor combination r...
Malignant Melanoma | Disease Landscape and Forecast | G7 | 2019
Although the malignant melanoma market has become increasingly crowded, an evolving trend of combining drug classes to create novel therapies is expanding treatment options for patients. While both...